• In October 2025, Copernic Catalysts, Inc. announced that, along with Schrödinger, it achieved the final milestone for their Neptune ammonia synthesis catalyst, which delivered over double the yield of competing products in real-world reactors while meeting agreed success benchmarks.
• This advancement addresses both profitability and sustainability by potentially boosting ammonia plant capacity, reducing energy consumption, and lowering CO2 emissions, factors central to the future of industrial chemical manufacturing.
• We’ll now explore how Schrödinger’s breakthrough in commercial-scale catalyst technology could influence its long-term investment narrative.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Schrödinger Investment Narrative Recap

Schrödinger’s investment case centers on the company’s ability to commercialize its computational platform beyond pharmaceutical drug discovery, with breakthrough technologies like the Neptune ammonia catalyst opening growth avenues in industrial chemicals. While the Copernic Neptune milestone strengthens Schrödinger’s story of innovation and revenue diversification, the company's largest short-term catalyst remains its progress in advancing drug discovery pipelines, particularly SGR-1505. Conversely, continued reliance on milestone payments and partner royalties still poses notable revenue uncertainty and volatility for shareholders.

The July 2025 expansion of Schrödinger’s collaboration with Ajax Therapeutics is especially relevant. It highlights ongoing interest from industry partners to use Schrödinger’s platform for next-generation drug discovery, tying directly into the broader narrative of multi-vertical technology adoption. These partnerships reinforce the company’s diversification efforts, yet leave open questions about the timing and consistency of future royalty and milestone flows.

But given the market’s optimism about new catalysts, one risk investors should be aware of involves...

Schrödinger's outlook anticipates $396.6 million in revenue and $34.8 million in earnings by 2028. This requires 18.6% annual revenue growth and a $216.1 million increase in earnings from current earnings of -$181.3 million.

Uncover how Schrödinger's forecasts yield a $27.30 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Investor fair values from the Simply Wall St Community range from US$27.00 to US$43.20 across six analyses, indicating sharply different outlooks. Many still see ongoing revenue volatility as a central issue for Schrödinger, prompting you to consider alternative interpretations of the company’s prospects.

Explore 6 other fair value estimates on Schrödinger - why the stock might be worth over 2x more than the current price!

Build Your Own Schrödinger Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Schrödinger research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Schrödinger research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Schrödinger's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've found 22 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.